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SEBUM PRODUCTION AND FRACTIONAL 17-KETOSTEROID
EXCRETION IN PARKINSONISM*
PETER E. POCHI, M.D., JOHN S. STRAUSS, M.D. AND
HERBERT MESCON, M.D.
Increased oiliness of the skin, particularly of
the forehead and cheek, has long been recognized
as a frequent accompaniment of postencephalitic
parkinsonism (1—5). This clinical finding has been
confirmed by measurements of lipid secretion
(6—9) and by histologic study which has demon-
strated an increase in sebaceous gland size to
account for the excessive lipid production (10).
However, the cause for this sebaceous gland en-
largement is unknown.
We have undertaken further study of patients
with parkinsonism in an attempt to delineate
the mechanism leading to the overdevelopment
of the sebaceous glands in these individuals. To
this end, in addition to measuring sebum produc-
tion, we have selected to study the androgen
production in these patients, since androgen is
the known primary stimulus for human sebaceous
gland development (11—13).
The specific questions we have sought to an-
swer are as follows: 1) whether increased se-
baceous gland activity occurs in idiopathic
Parkinson's disease as well as in the postenceph-
alitic syndrome; 2) whether an increase can be
demonstrated in other neurologic conditions asso-
ciated with organic brain damage; and 3) whether
hypersecretion of the sebaceous glands can be
correlated with excessive production of andro-
gens, as measured by their urinary end products,
the neutral 17-ketosteroids.
METHODS
Sebum production was measured by the method
previously described by the authors (14). In brief,
after suitable preparation of the forehead collec-
tion site, which usually measured 6.5 square
centimeters, the lipid was collected over a three-
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hour period on ether washed cigarette papers held
in place by a bandage encircling the forehead. The
lipid was subsequently extracted and assayed by
gravimetric technics.
Twenty-four hour urine specimens were col-
lected and assayed for fractional neutral 17-keto-
steroids. Following hydrolysis of the 17-keto-
steroid conjugates in the urine with the use of
Glusulase®t (containing glucuronidases and
sulfatases), the individual ketosteroids were
separated by descending paper partition chroma-
tography in a ligroin/propylene glycol system
after the method of Zaffaroni (15). Appropriate
areas were eluted in accordance with the mobilities
of pure crystalline steroid standards. These
individual fractions were then measured by the
Zimmerman reaction (16).
The individual ketosteroids possess varying
degrees of biologic androgenic potency (17).
Therefore, it is essential to measure the individual
17-ketosteroids rather than rely on the conven-
tional measurement of total 17-ketosteroids. For
example, Table 1 lists the relative androgenic
activity of the five 17-ketosteroids normally
isolated by the fractionation procedure described
above. Androsterone and etiocholanolone, which
normally together comprise roughly one-half of
the urinary 17-ketosteroids, are stereoisomers.
Yet, their biologic androgenic potency is decidedly
different, androsterone being highly active and
etiocholanolone being entirely devoid of such
activity. For example, an absolute increase in
etiocholanolone production alone would be
reflected by an elevated total 17-ketosteroid
excretion; there would be no increase in biologic
androgenic activity. Thus, it is the relative
concentration of the individual 17-ketosteroids
rather than the total which is of significance as an
index of androgenic potential. Table 1 also lists
the source of the individual 17-ketosteroids found
in the urine. All five are derived from the adrenal
gland, with androsterone and etiocholanolone
being additionally contributed to by the metabo-
lism of testicular androgen. Elevation of andros-
terone and etiocholanolone to the exclusion of
the other ketosteroids might reflect increased
testicular androgen production, whereas elevation
of all five steroids might instead reflect increased
adrenal androgen production, or possibly both.
Thirty-seven patients with parkinsonism, 40
patients with other neurologic diseases and 22
normal controls of comparable ages were studied.
Of the parkinsonian group, three had unequivocal
t Endo Laboratories Inc., Richmond Hill,
New York.
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%
17-Ketosteroid Source Androgen
Potency*
Androsterone adrenal, testis 100
Dehydroepiandros-
terone adrenal 28
li-Hydroxyandros-
terone adrenal <2.5
li-Ketoetiocholan-
olone adrenal 0
Etiocholanolone. . . . adrenal, testis 0
* Based upon comparison of weight increase
in chick comb upon application of individual
ketosteroids (17). Androsterone is reference
standard (100%).
postencephalitic disease, whereas the remainder
were of the idiopathic type. Of the patients with
other neurologic disorders, there were thirty-five
with a variety of conditions (cerebrovascular
thrombosis, hemorrhage and embolism; multiple
sclerosis; brain tumors, primary and metastatic;
and Wernicke's encephalopathy), and five with
disorders involving the basal ganglia (Hunting-
ton's chorea, Wilson's disease). Sebum production
studies were done on all subjects. With the excep-
tion of seven individuals, these were repeated at
least once. The urine studies of fractional 17-keto-
steroids were performed on a selected group of
fourteen male patients with parkinsonism, chosen
for the adequacy of the 24 hour urine collection as
determined by creatinine excretion. For compari-
son, the same studies were carried out on the
urines of ten healthy male subjects of a similar
age group.
RESULTS
Sebum Production
The values for lipid output in all of the pa-
tients appear in Tables 2 and 3. In the male sub-
jects the average lipid production values, cx-
pressed as milligrams of lipid per ten square
centimeters per three hours, were as follows:
parkinsonism, 3.76; neurologie controls, 2.86;
and normal controls, 2.10. For the females, the
figures were: parkinsonism, 1.89; neurologie
controls, 1.07; and normal controls, 0.68. In both
males and females, the mean sebum value for the
group of patients with parkinsonism was sig-
nificantly elevated as compared to that of the
normal subjects (P < 0.01). The patients with
other neurologic disorders also showed a some-
what elevated sebum level as compared to nor-
mals, although the difference of the mean was
Parkinsonism
(age 38—73)
Neurologic
controls
(age 34—73)
Normal
controls
(age 39—70)
7.13 4.90 4.66
5.71* 4.65 3.74
5.41 4.63f 3.06
4.88 4.62 3.06
4.63 4.18 2.63
453* 3.82 2.54
4.49 3.72 2.53
4.43 3.60 2.35
4.02 3.17 2.16
3.95 3.02 2.14
3.77 3.02 2.04
3.71 2.99 1.94
3.55 2.85 1.91
3.40 2.74 1.83
3.33 2.73f 1.68
3.20 2.67 1.46
3.16 2.49f 1.35
3.16 2.46 1.31
2.88 2.17 1.08
2.88 2.0Sf 1.05
2.68 2.06 0.90
1.84 1.94 0.83
1.76 1.65
1.64 1.6Sf
1.58
1.16
0.78
Mean & S.D. 3.76 2.86 2.10
Postencephalitic syndrome.
f Huntington's ehorea.
f Wilson's disease.
barely short of statistical significance. However,
since there were more than twice as many males
as females tested for sebum production, the male
group is a more valid representative sample for
study. And, as all but 20 per cent of male subjects
were in the 50—70 year age range, a statistical
comparison which excludes those few patients
who fall outside of this age group reveals not
only a significant increase in the production of
sebum in the parkinsonian patients (P < 0.01)
but also in the neurologie controls as well
(0.05 > P > 0.02).
The data for all male subjects are summarized
TABLE 1 TABLE 2
Sebum production, mates
Milligrams of lipid/ten square centimeters/three hours
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TABLE 3
Sebum production, females
Milligrams ot lipid/ten square centimeters/three hours
Parkinsonism
(age 4777)
Neurologic
Controls
(age 50—78)
Normal
Controls
(age 57—72)
4.15
3.72
2.99
2.32
2.13
2.07
1.66
1.28
1.28
0.93
0.90
0.77
0.31
3.42
1.84
1.38
1.36
1.14
1.08
0.91
0.73
0.60
0.44
0.41
0.30
0.27
0.97
0.86
0.85
0.67
0.66
0.65
0.51
0.50
0.43
Mean & S.D. 1.89 1.07 0.68
Posteneephalitie syndrome.
in Fig. 1 which again illustrates the highly sig-
nificant rise in lipid secretion in the patients with
parkinsonism. Unfortunately, we were able to
test only two patients with the postencephalitic
syndrome. As expected their lipid production was
exceedingly high. However, the highest indi-
vidual sebum level was encountered in a patient
with idiopathic Parkinson's disease. In fact, in
the group of patients with idiopathic Parkinson's
disease, there was a highly significant difference
in lipid production as compared to normal
(P .c 0.01).
Urine Studies
Tables 4 and 5 list the values for total and
fractional urinary 17-ketosteroid output in pa-
tients with parkinsonism and ia normal controls,
respectively. There was no significant difference
in the mean total 17-ketosteroid excretion be-
tween the two groups (8.8 mg. for the parkin-
sonian group and 9.6 mg. for the normal controls).
Furthermore, except for androsterone, no sig-
nificant variation in the relative amounts of the
individual ketosteroids was observed between
the two groups. With androsterone there was a
significant decrease in the patients with parkin-
sonism as compared to normal. Two other ab-
normalities were noted in the parkinsonian
r'
Fso. 1. Mean sebum output values in various
groups of male subjects studied. Figures within
bars represent number of individuals in each
group.
group. First, there was a rather marked variation
in the amounts of dehydroepiandrosterone and
etiocholanolone within the group of patients with
parkinsonism as compared to the group of normal
controls. Second, an unknown compound, labeled
fraction X, was detected in the chromatograms of
two patients with parkinsonism. It appeared on
the paper between 11-hydroxyetiocholanolone
and dehydroepiandrosterone, and was found to
absorb ultraviolet light. However, its identity at
present is unknown, and there is, of course, no
certainty that it is a steroid. Nonetheless, the
striking feature of this substance was that of all
subjects tested it occurred only in the urines of
those two patients with the highest levels of
sebum output. Except for this finding, there was
no correlation between sebum production and
fractional or total 17-ketosteroid excretion.
Salicylate ingestion has been reported to alter
the urinary excretion of neutral 17-ketosteroids
(18), but none of the patients were receiving
salicylates at the time of the urine collection.
Nearly all the patients were being treated with
some type of anti-parkinsonian drug, but there
was no correlation between 17-ketosteroid values
and the drug employed.
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TABLE 4
DISCUSSION
The sebum production studies have again con-
firmed the presence of increased sebaceous gland
activity in parkinsonism. The finding of elevated
lipid levels in idiopathic Parkinson's disease, as
well as in the postencephalitic syndrome, de-
serves comment, since it is not always clear from
the reports of previous investigators what type
of parkinsonism was actually being studied. On
occasion the thought has been expressed that the
heightened sebaceous secretion seen in post-
encephalitic parkinsonism does not occur in the
idiopathic disease (4, 19). Our findings certainly
do not support this contention. Indeed, the pres-
ence of increased lipid secretion in other neuro-
logic conditions as well seems to indicate that a
Total 17-ketosteroid mg/24 hrs
Total and fractional urinarj 17-ketosteroids in parkinsonism (males, age 47—73)
Androsterone Dehydroepi-androsterone
mg
1 1-Hydroxy-
androsterone
1l-Ketoetio—
cholanolone
Etiocholano-
lone Fraction X
4.5
5.0
6.6
6.7
7.2
7.4
8.1
8.9
9.0
9.5
10.8
12.1
12.6
14.3
%
20.0
18.0
16.7
20.9
11.1
24.3
24.7
33.7
17.8
16.8
14.8
3.3
19.0
7.0
0.9
0.9
1.1
1.4
0.8
1.8
2.0
3.0
1.6
1.6
1.6
0.4
2.4
1.0
mg
0.3
0.8
0.3
0.4
.5
0.6
1.0
0.5
0.9
2.0
0.7
4.9
4.4
0.4
%
6.7
16.0
4.5
6.0
34.7
8.1
12.3
5.7
10.0
21.1
6.5
40.5
34.9
2.8
mg
0.8
0.9
1.9
1.0
1.6
1.3
1.7
1.7
1.7
1.7
2.2
2.3
2.4
2.5
%
17.8
18.0
28.8
14.9
22.3
17.6
21.0
19. 1
18.9
17.9
20.4
19.0
19.0
17.5
mg
1.2
1.4
2.1
0.8
1.5
1.1
1.0
1.9
1.7
2.0
3.5
1.5
2.0
3.3
%
26.6
28.0
31.8
11.9
20.8
14.9
12.3
21.3
18.9
21.1
32.4
12.4
15.9
23.1
mg %
1.0 10.5
1.0 9.2
mg
1.3
1.0
1.2
3.1
0.8
2.6
2.4
1.8
3.1
1.2
1.8
3.0
1.4
7.1
%
28.9
20.0
18.2
46.3
11.1
35.1
29.7
20.2
34.4
12.6
16.7
24.8
11.2
49.6
Mean & S.D. 8.8 17.7 15.0 19.4 20.8 25.6 1.4
TABLE 5
Total and fractional urinary 17-ketosteroids in normal males, age 50—70
Total 17-ketosteroid mg/24 hrs
A d tn ros crone
mg %
Dehydroepi-
androsterone
-
mg %
il-Hydroxy-
androsterone
mg %
il-Ketoetiocho-
lanolone
mg %
Etiocholano-
lone
mg %
1.0 18.5
2.6 35.1
2.7 35.1
1.2 14.8
2.0 23.8
2.0 23.3
2.5 23.4
4.9 40.5
4.1 31.6
4.5 31.4
5.4
7.4
7.7
8.1
8.4
8.6
10.8
12.1
13.0
14.3
2.0
1.7
2.4
1.7
2.0
2.1
3.0
2.2
2.2
3.3
37.0
23.0
31.1
21.0
23.8
24.4
28.1
18.2
16.9
23.1
0.5
0.8
0.6
1.2
0.7
1.2
2.1
0.8
1.3
2.5
9.3
10.8
7.8
14.8
8.3
13.9
19.6
6.6
10.0
17.5
0.8
1.0
0.7
2.0
2.0
2.0
1.3
1.4
1.9
1.8
14.8
13.5
9.1
24.7
23.8
23.3
12.1
11.6
14.6
12.6
1.1
1.3
1.3
2.0
1.7
1.3
1.8
2.8
3.5
2.2
20.4
17.6
16.9
24.7
20.3
15.1
16.8
23.1
26.9
15.4
Mean & S.D. 9.6 24.7 11.9 16.0 19.7 27.8
±8.2
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variety of neurologie diseases affecting the brain
may induce the same sebaceous gland response.
There has been some evidence for this in the past.
Serrati (6), using rather crude methods, found
sebum output to be increased in various neuro-
logic diseases. More recently, a report has de-
scribed the finding of elevated surface lipid levels
in patients with epilepsy (9). Because the degree
of hypersecretion seems to be greater in parkin-
sonism, the question arises as to the possible
influence of the extrapyramidal systern on sebum
secretion. In our patients in the neurologic control
group there were five eases of non-parkinsonian
disorders thought to involve the basal ganglia
(four with the rigid form of Huntington's ehorea
and one with Wilson's disease). The mean sebum
level of these patients was 2.72 mg. of lipid per
ten square centimeters per three hours, a figure
slightly lower than the average of the neurologie
control group as a whole and considerably lower
than that of the patients with parkinsonism.
Thus, there is the suggestion that damage to the
basal ganglia, per se, is not specific for the de-
velopment of glandular hyperplasia in parkin-
sonism.
It is also worth noting that the lipid levels in
the females, group for group, were consistently
lower than in the males. In fact, the value for
normal males exceeded that of females with
parkinsonism. These findings are consistent with
those of other investigators who have shown a
difference between sebum levels of middle-aged
to aged males and females (7, 9, 20—22).
The problem that remains to be solved is the
specific cause for the increase in sebaceous gland
activity in parkinsonism and other neurologie
diseases. It is reasonable to suppose that a neuro-
logic disturbance would affect these glands
directly, but as there is no evidence for sebaeeous
gland innervation in humans (10, 23-27), this
theory is properly dismissed. Since it is known
that androgens are a prime stimulus for sebaeeous
gland development at puberty, it is logical to
hypothesize that chronic neurologie disease might
lead to stimulation of the hypothalamic-pituitary-
adrenal system, resulting in an increase in adrenal
androgen production. However, our urine studies
of male patients with parkinsonism have failed
to reveal an increase in androgen secretion as
measured by fractional 17-ketosteroids.
Before hastily discounting the role of androgens
or of the adrenal gland in the excitation of the
sebaeeous glands in these patients, one should
bear certain considerations in mind. First, the
effect of these various compounds upon the se-
baceous gland is unknown. The relative biologic
androgen potency of the individual 17-keto-
steroids has already been pointed out (Table 1),
but it is not all certain that the sebaceous gland
would necessarily respond in a similar qualitative
or quantitative fashion as the chick's comb or
other susceptible end organ. Second, it is re-
motely possible that some yet unidentified
ketosteroid or other substance such as that found
in the urines of two patients in this study is
singularly responsible for sebaceous gland stimu-
lation. Third, the rather bizarre fluctuations ob-
served in the dehydroepiandrosterone and etio-
eholanolone fractions in parkinsonism but not in
the control group suggest that at least in some of
the patients the intermediary metabolism of
androgens may somehow have been disturbed.
Adrenal stimulation and suppression studies may
possibly have helped to clarify the issue, but these
were not carried out. Fourth, the possibility exists
that the urines may have contained biologically
active androgens lacking the 17-keto configura-
tion and thus being detectable only by biologic
assay. Finally, there may have been an imbalance
between the relative amounts of free and con-
jugated 17-ketosteroids in the urines of patients
with parkinsonism versus normals.
The exact mechanism for the sebaeeous gland
hyperplasia and the resultant increase in seburn
output in these patients remains obscure. Our
failure to demonstrate an increase in androgen
secretion in these patients might be interpreted as
evidence for the validation of other theories. For
instance, Lorinez and co-workers demonstrated
a sebotropie factor derived from the anterior
pituitary glands of hogs (28). This agent was
capable of increasing the size of the sebaeeous
glands in rats when administered concomitantly
with large amounts of progesterone (29). This
substance has not been demonstrated in man,
and to our knowledge there are no reported
studies of its effect upon the human sebaeeous
gland. As such, the possible role of this sebotropie
factor in the control of human sebaeeous secre-
tion must remain an open question.
SUMMARY
1. Sebum production is significantly increased
in patients with parkinsonism. This increase oc-
curs in the idiopathic disease as well as in the
posteneephalitie syndrome.
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2. Sebum secretion is also higher than normal
in patients with other neurologic diseases, al-
though to a lesser degree than in parkinsonism.
3. Comparison of the total and fractional 24
hour urinary 17-ketosteroid excretions between
males with parkinsonism and normal controls of
the same age does not disclose any changes to
account for the rise in sebum production.
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DISCUSSION
DR. MENDELSON (Detroit, Michigan): I would
like to know how soon after one has encephalitis
and develops parkinsonism does the increase take
place. Or, do you know how soon afterward the
increased sebum is produced?
Secondly, in the people who have shown extra-
pyramidal symptoms on certain drugs, have you
been able to observe these people during their
attack to see if there is any increase in sebaceous
activity just during this brief time spnn?
DR. STEPHEN ROTHMAN (Chicago, Illinois):
Similar results in postencephalitie parkinsonism
were obtained by Serrati in 1938. In addition, he
found oleic seborrhea in a great number of differ-
ent diseases of the central nervous system.
The best explanation for this phenomenon is
that hypothalamic disease leads to an overpro-
duction of the sebotropic factor of Lorinez. This
may happen without increase of androgen exere-
tion because the sebotropic and gonadotropic
factors are clearly distinguishable.
DR. PETER E. POCHI (in closing): I wish to
thank the discussors for their comments.
Dr. Mendelson, in postencephalitic parkin-
sonism, the latent period between the virus attack
and the onset of parkinsonian sequelae is quite
variable, ranging from a few weeks to many
years. In the three patients we studied with this
syndrome, the intervals were 14, iS and 22 years.
We did not investigate patients with acute extra-
pyramidal-like symptoms resulting from pheno-
thiazine drugs.
Dr. Rothman, we recognize, of course, the
possibility that sebotropin may be present in
humans. While these particular studies do not
deny the theory of its existence, neither certainly
do they confirm it.
